Portal de Periódicos da CAPES

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

2017; Elsevier BV; Volume: 130; Issue: 6 Linguagem: Inglês

10.1182/blood-2017-04-779447

1528-0020

Michael Amatangelo, Lynn Quek, Alan H. Shih, Eytan M. Stein, Mikhail Roshal, Muriel D. David, Benoît Marteyn, Noushin Farnoud, Stéphane de Botton, Olivier Bernard, Bin Wu, Katharine Yen, Martin S. Tallman, Elli Papaemmanuil, Virginie Penard‐Lacronique, Anjan Thakurta, Paresh Vyas, Ross L. Levine,

Myeloproliferative Neoplasms: Diagnosis and Treatment

Key Points Enasidenib inhibits mIDH2, leading to leukemic cell differentiation with emergence of functional mIDH2 neutrophils in rrAML patients. RAS pathway mutations and increased mutational burden overall are associated with a decreased response rate to mIDH2 inhibition.